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Materials and Methods: The error detection system 
considered here consists of three layers: 1) a software 
algorithm to detect errors in a treatment plan based on hard-
coded rules, 2) a software algorithm to detect errors based 
on a probabilistic Bayesian network model which draws from 
prior radiotherapy plans, and 3) EPID dosimetry performed 
either prior to treatment or during treatment. The multi-
layered system is intended to detect different classes of 
error and provide a 'defense in depth'. The system was 
validated against a radiotherapy incident database consisting 
of 2,599 reports collected over a 2.5 year period. Results 
presented here focus on external beam treatments with 
photon beams. The sensitivity and specificity of the 
probabilistic Bayesian error network was validated by 
introducing simulated errors and benchmarking against 
expert observers. 
Results: The sensitivity of the multi-layered system is 91%. 
EPID dosimetry alone provide a 74% sensitivity for, but only if 
used during the treatment (i.e. 'in vivo'). If performed prior 
to treatment the sensitivity falls to 6%. The rules-based 
algorithm has a sensitivity of 24%, while the probabilistic 
network has a sensitivity of 25%. The three layers provide 
complimentary detection sensitivity as observed in 
combination studies. The ROC analysis of the probabilistic 
Bayesian error network showed an AUC of 0.98, 0.88, and 
0.89 for the brain, lung and breast networks respectively. 
This compares favorably to expert observers using brain cases 
where an AUC of 0.90±0.01 was observed. 
Conclusions: When used in combination, the multi-layer 
automatic detection system is capable of detecting a vast 
majority of errors that are actually observed in clinical 
radiotherapy practice. Key components are EPID dosimetry 
performed during treatment and a probabilistic error 
prediction network. While eachcan be used on its own, these 
approaches are most effective when used in combination. 
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Purpose/Objective: EPID based in-vivo dosimetry is one of 
the most efficient and effective methods of confirming the 
correct delivery of complex radiotherapy. Software used to 
perform EPID in-vivo dosimetry typically needs to be 
commissioned for every linac and energy combination where 
EPID data is to be used. Previous work has demonstrated that 
a single energy-specific calibration model can be used to 
dosimetrically analyse EPID data acquired from multiple 
linacs by determining a linac-specific offset factor. Using this 
method has reduced the per-linac commissioning time for 
EPID based in-vivo dosimetry from 11 hours to 30 minutes.  
Auditing of the results of EPID in-vivo dosimetry performed 
on 7 clinical linacs has confirmed the validity of using these 
linac-specific offset factors. Investigation of the lifetime 
response of EPID panels has attributed the cause of these 
offset factors to differences in the software calibration of 
EPID panels rather than the dosimetric characteristics of the 
linac. 
Materials and Methods: The EPID in-vivo software was fully 
commissioned for an Elekta MLCi2 linac at 6 & 10MV and an 
Elekta Beam Modulator linac at 15MV. These energy-specific 
models were then used to analyse EPID images acquired on 
multiple linacs. From this a series of linac-specific offset 
factors was determined that would allow an EPID dosimetry 
model commissioned for one linac to be used on multiple 
other linacs. By comparing EPID in-vivo results from patients 
treated on each of these linacs over a period of 5 years the 
validity of this offset factor approach could be determined. 
The change in the linac specific offset factor has be tracked 
along the lifetime of several EPID panels. Changes in EPID 
panel response as a result of image recalibration were 
correlated with changes in the linac-specific offset factors 
applied to EPID dosimetry results. 
Results: The EPID in-vivo results of over 4000 patients 
acquired were analysed. No significant differences were 
found between patient treatments from different linacs, 
thereby validating this commissioning approach. 
The linac-offset factors determined were found to vary 
significantly (as much as 34%) when an EPID underwent image 
software calibration, despite there being no change in 
imaging or treatment hardware. This implies that it is the 
software determined response of the EPID panel and not the 
dosimetric characteristics of the linac that have the greatest 
impact on offset factors determined. 
Conclusions: The in-vivo results of over 4000 patients has 
confirmed the validity of using an energy-specific EPID in-vivo 
dosimetry model on multiple linacs when combined with 
linac-specific offset factors. Furthermore, by investigating 
the behaviour of this offset factor along the lifetime of an 
EPID panel the cause of this offset factor can be attributed to 
the software calibration of the EPID panel rather than 
dosimetric characteristics of the linac.  
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Purpose/Objective: The idea of using gold nanoparticles 
(GNP) as a high atomic number material in a tumor and 
exposing them to low energy x-rays to achieve dose 
enhancement (DE) has been previously explored. However, 
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the low penetration of kV x-rays limits their useful depth 
range. An interesting solution is to bring the x-ray tube close 
to GNP-loaded tumors. But this can result in non-uniform 
tumor dose distributions. Although a sharp dose falloff is 
useful in brachytherapy, it may not be desirable for thick 
tumors. Here, DE was investigated with the additional aim of 
creating tumor dose uniformity, the idea being that using 
different concentrations of GNP within the tumor can be 
potentially useful as a means of compensating dose falloff.  
Materials and Methods: A miniature intraoperative/ 
brachytherapy x-ray tube with 40-50 kVp photon spectra was 
simulated using MCNP. The tube was simulated in a water 
phantom to obtain its AAPM TG-43 parameters and the model 
was validated against the results of other investigators. The 
tube was first simulated underneath a virtually segmented 
tissue with and without the gold GNP. Then, a 1 cm thick 
tumor was further subdivided into layers to calculate the 
dose distribution. Next, layers of different thicknesses at 
various distances from the tube and also different 
concentrations of GNP were simulated. Then, DE curves were 
plotted for different densities of GNP, namely, 7, 15, and 30 
mg/ml. To allow the use of MCNP for these simulations, the 
GNPs were assumed to be uniformly distributed and also 
sufficiently small to make electron absorption in them 
negligible. Finally, to obtain better DE and dose homogeneity 
concomitantly, the distribution of GNP concentrations (in the 
range 7-30 mg/ml) of the layers were increased progressively 
with depth in tumor by adopting different models, namely, in 
linear (model 1), quadratic (model 2), and exponential 
(model 3) fashions, and their effects were investigated 
separately. 
Results: Although increasing the concentration of GNP 
uniformly within the tumor produced DE at low depths, it 
caused further inhomogeneity due to the additional 
attenuation because of the higher atomic number of the GNP. 
However, increasing the GNP concentration progressively 
with depth in the tumor produced a better homogeneity 
index as well as mean DE. Mean DEs, relative to the case of 
no GNP, for the progressive models 3, 2 and 1 and the 
uniform GNP (7 mg/ml) distribution model were found to be 
50%, 51%, 48%, and 26%, respectively. Also, model 3 offered 
the best homogeneity index. 
Conclusions: Under these conditions, progressive addition of 
GNP with depth in tumor can potentially improve both mean 
DE and dose homogeneity, while the amount of the 
improvement is somewhat dependent on the model of 
concentration increase. Having shown this potential 
improvement, further studies are required to test the 
practical feasibility and implementation of this idea. 
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Purpose/Objective: In November 2014, Gantry-2 (G2) started 
to be used clinically. This second generation gantry is an iso-
centric, compact Gantry with a diameter of only 7.5m and 
with fast 3D scanning with changes in the proton range of 
5mm in water being achieved within 80ms and the dose being 
delivered using narrow pencil beams (3-5 mm) down to 
energies of 70MeV. We report here on our initial experiences 
of this gantry after 1 year of operation. 
Materials and Methods: From November 2013 to November 
2014, 18 patients have been treated with G2, with a 
combination of Single Field Uniform Dose (SFUD) and 
Intensity Modulated Proton Therapy (IMPT). Absolute dose, 
beam range and the spot position have been measured for 
various combinations of beam energies and gantry angles as 
part of the daily QA check procedure. Absolute dose is 
measured in the centre of a 6×6×6 cm3 box using an 
ionization chamber positioned within a PMMA phantom. 
Depth doses are measured using a multilayer Ionization 
Chamber (MLIC), with the position and dimension of the 
delivered spots being verified with ministrip chambers 
embedded in the daily QA phantom.  Patient specific dose 
verifications are performed with a commercial PTW 2D array 
seven2.9 for every field before being applied to the patient 
and have been analyzed using the gamma (3%/3 mm) 
evaluation. Additionally, delivered dose distributions have 
been reconstructed in the patient geometries using a 
machine-log-file driven independent dose calculation. 
Results: Figure 1 shows an example of the plan and DVHs for 
the first patient treated at G2.  In total, 37 treatment series 
have been applied. The number of fields per plan ranged 
from 3 to 4 (mean, 3.1). PTV volumes are in the range 20-220 
ml. The current delivery rate of about 3000 spots per minute 
translates into a median treatment time per individual field 
of 37s (mean of 1 minute and 49s and standard deviation of 
59s). Results of the daily QA checks of absolute dose and 
beam range are excellent with measured doses and ranges 
differing from the expected values by < 0.2% and by <0.1 mm 
respectively.  Patient specific field verifications show a very 
good agreement between measurement and calculation with 
more than 98% of points over all fields passing the gamma 
criteria. Finally, maximum single point differences of <2.5% 
have been found between the planned and the reconstructed 
delivered doses calculated from the log-files over all series.  
 
 
Conclusions: The introduction of G2 into clinical routine has 
been smooth and has resulted in excellent reproducibility and 
delivery accuracy. Although we have deliberately started 
with a cautious approach in terms of patient load and target 
location, our current experience clearly indicates the scope 
for increased patient throughput and expanded indications in 
the near future. 
